Effects of Systemic Chemotherapy on Tear Volume in Cancer Patients
Journal of Ophthalmic and Optometric Sciences,
Vol. 8 No. 4 (2024),
22 September 2024
,
Page 7-15
https://doi.org/10.22037/joos.v8i4.46977
Abstract
Purpose: This study aimed to evaluate changes in tear volume and dry eye symptoms in cancer patients following first time systemic chemotherapy.
Patients and Methods: In this cross-sectional study, cancer patients undergoing chemotherapy for the first time with different drug regimens were evaluated before and after treatment. Assessments included the Schirmer’s test, the Ocular Surface Disease Index questionnaire, and a comprehensive eye examination for all patients.
Results: A total of 60 patients (120 eyes) with a mean age of 52.07 ± 13.047(range: 18-80 years) were examined. Of these patients 53.3% (n = 32) were female. The mean Schirmer’s test score was 9.17 ± 8.65 mm before chemotherapy and 10.02 ± 9.82 mm after chemotherapy; showing no statistically significant difference (P = 0.865). The only group showing a significant increase in mean Schirmer’s test score was patients older than 40 years old (P < 0.01).
Conclusion: Although changes in mean tear volume following systemic chemotherapy were not significant - except among patients over 40 years old - further studies with larger sample sizes and longer follow-up periods are warranted.
- Tear volume, Schirmer’s test, OSDI, Dry eye, Chemotherapy, Cancer.
How to Cite
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407-19.
Cho AR, Yoon YH, Kim JG, Kim YJ, Lee JY. Uveoretinal Adverse Effects Presented during Systemic Anticancer Chemotherapy: a 10-Year Single Center Experience. J Korean Med Sci. 2018;33(7):e55.
Tsubota K, Yokoi N, Shimazaki J, Watanabe H, Dogru M, Yamada M, et al. New Perspectives on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society. Ocul Surf. 2017;15(1):65-76.
Yazdani M, Elgstoen KBP, Rootwelt H, Shahdadfar A, Utheim OA, Utheim TP. Tear Metabolomics in Dry Eye Disease: A Review. Int J Mol Sci. 2019;20(15).
Willcox MDP, Argueso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017;15(3):366-403.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92.
Kang TS, Cho J, Kim J, Sung JY, Kim JM, Kim KN, et al. Modified ocular surface disease index as a screening criteria for dry eye syndrome presenting after successful dacryocystorhinostomy. PLoS One. 2021;16(2):e0247168.
The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):93-107.
Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51(1):19-40.
Skolnick CA, Doughman DJ. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens. 2003;29(2):134-5.
Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98(3):504-7.
Taylor A, Olver I, Sivanthan T, Chi M, Purnell C. Observer error in grading performance status in cancer patients. Support Care Cancer. 1999;7(5):332-5.
Midorikawa-Inomata A, Inomata T, Nojiri S, Nakamura M, Iwagami M, Fujimoto K, et al. Reliability and validity of the Japanese version of the Ocular Surface Disease Index for dry eye disease. BMJ Open. 2019;9(11):e033940.
Serruya LG, Nogueira DC, Hida RY. Schirmer test performed with open and closed eyes: variations in normal individuals. Arq Bras Oftalmol. 2009;72(1):65-7.
Cloutier AO. Ocular side effects of chemotherapy: nursing management. Oncol Nurs Forum. 1992;19(8):1251-9.
Tsubota K, Pflugfelder SC, Liu Z, Baudouin C, Kim HM, Messmer EM, et al. Defining Dry Eye from a Clinical Perspective. Int J Mol Sci. 2020;21(23).
Huillard O, Bakalian S, Levy C, Desjardins L, Lumbroso-Le Rouic L, Pop S, et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer. 2014;50(3):638-48.
Griffin JD, Garnick MB. Eye toxicity of cancer chemotherapy: a review of the literature. Cancer. 1981;48(7):1539-49.
Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy. 2006;26(6):853-67.
Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci. 1997;74(8):624-31.
Tsalic M, Gilboa M, Visel B, Miller B, Haim N. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol. 2006;23(1):57-61.
Mansur C, Pfeiffer ML, Esmaeli B. Evaluation and Management of Chemotherapy-Induced Epiphora, Punctal and Canalicular Stenosis, and Nasolacrimal Duct Obstruction. Ophthalmic Plast Reconstr Surg. 2017;33(1):9-12.
Esmaeli B, Ahmadi MA, Rivera E, Valero V, Hutto T, Jackson DM, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol. 2002;120(9):1180-2.
Park J, Kim J, Baek S. Clinical features and treatment outcomes of patients with tearing after chemotherapy. Eye (Lond). 2019;33(5):746-53.
Loprinzi CL, Love RR, Garrity JA, Ames MM. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity. Cancer Invest. 1990;8(5):459-65.
Lee V, Bentley CR, Olver JM. Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy. Eye (Lond). 1998;12 ( Pt 3a):343-9.
Matsumoto Y, Dogru M, Sato EA, Ibrahim OM, Tatematsu Y, Ogawa Y, Tsubota K. S-1 induces meibomian gland dysfunction. Ophthalmology. 2010;117(6):1275.e4-7.
Asencio-Durán M, Fernández-Gutiérrez E, Larrañaga-Cores M, Klein-Burgos C, Dabad-Moreno JV, Capote-Díez M. Ocular side effects of oncological therapies: Review. Arch Soc Esp Oftalmol (Engl Ed). 2024;99(3):109-132.
Fraunfelder FT, Fraunfelder FW. Oral Anti-Vascular Endothelial Growth Factor Drugs and Ocular Adverse Events. J Ocul Pharmacol Ther. 2018;34(6):432-5.
Sitzia J, Hughes J, Sobrido L. A study of patients' experiences of side-effects associated with chemotherapy: pilot stage report. Int J Nurs Stud. 1995;32(6):580-600.
Doroshow JH, Locker GY, Gaasterland DE, Hubbard SP, Young RC, Myers CE. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer. 1981;48(10):2158-62.
Ma J, Pazo EE, Zou Z, Jin F. Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study. Breast. 2020;53:164-71.
- Abstract Viewed: 77 times
- pdf Downloaded: 107 times
